articleTop 10% cited

Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

Clinical Cancer Research · 2004 · Vol. 10(20) · pp. 6897–6904

W. Jeffrey Allard✉(Eon Corporation (United States))Jeri Matera(Eon Corporation (United States))Michael Craig Miller(Eon Corporation (United States))Madeline Repollet(Eon Corporation (United States))Mark C. Connelly(Eon Corporation (United States))Chinthalapally V. Rao(Eon Corporation (United States))Arjan G.J. Tibbe(Eon Corporation (United States))Jonathan W. Uhr(The University of Texas Southwestern Medical Center)Leon W.M.M. Terstappen(Eon Corporation (United States))

View via DOI Publisher page

Abstract

The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs. CTCs are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.

Cancer Cells and Metastasis Cancer Genomics and Diagnostics 3D Printing in Biomedical ResearchCirculating tumor cellMedicineInternal medicineOncologyProstatePathologyLungColorectal cancerCancerCarcinoma

MeSH terms

AdultAutomationBiological AssayCarcinomaCytological TechniquesFemaleHumansMaleMiddle AgedNeoplastic Cells, CirculatingNeoplasm MetastasisSensitivity and SpecificityReproducibility of ResultsCase-Control Studies

Citations

2,489

FWCI

8.60

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

Cited by

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers